0309 GMT - Pro Medicus's proven ability to maintain a steady cadence of new contracts helps justify the imaging tech provider's premium valuation, according to its bulls at Goldman Sachs. The investment bank's analysts also see the Australia-listed company's A$24 million contract with NYU Lagone Health as evidence of the ability to upsell additional services to existing customers. They tell clients in a note that there is potential for Pro Medicus to renew or upgrade existing customers on favorable terms. GS lifts its target price 14.5% to A$221.00 and keeps a buy rating on the stock, which is up 10% at A$251.73. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 27, 2024 22:09 ET (03:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。